Possible benefit of consolidation therapy with high-dose cytarabine on overall survival of adults with non-promyelocytic acute myeloid leukemia

por Azevedo, M.C., Velloso, E.D.R.P., Buccheri, V., Chamone, D.A.F., Dorlhiac-Llacer, P.E.
Publicado 2014

Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results

por Hughes, T P, Leber, B, Cervantes, F, Spector, N, Pasquini, R, Clementino, N C D, Schwarer, A P, Dorlhiac-Llacer, P E, Mahon, F-X, Rea, D, Guerci-Bresler, A, Kamel-Reid, S, Bendit, I, Acharya, S, Glynos, T, Dalal, D, Branford, S, Lipton, J H
Publicado 2017

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

por Hochhaus, A, Saglio, G, Hughes, T P, Larson, R A, Kim, D-W, Issaragrisil, S, le Coutre, P D, Etienne, G, Dorlhiac-Llacer, P E, Clark, R E, Flinn, I W, Nakamae, H, Donohue, B, Deng, W, Dalal, D, Menssen, H D, Kantarjian, H M
Publicado 2016